Clinical Trials & Research
Search Clinical Trials
Clinical Trials
New Search
| Title | A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients aged 10-24 years. |
|---|---|
| Full Title | A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients aged 10-24 years. |
| Disease/Condition | Pediatric Endocrinology |
| Description | |
| Eligibility Criteria | Click here for eligibility requirements |
| Principal Investigator | Rubina Heptulla |
| Contact Name | Ranjitha Katikaneni |
| Contact Email | rkatikan@montefiore.org |
| Protocol Number | IRB# 16-10-255-01 |
| Inclusion/Notes | This information was obtained from ClinicalTrials.gov. |
| Status | Enrolling |
| Adult Clinical Trial | No |
| Pediatric Clinical Trial | No |
| Adult, Pediatric, Both | Adult |
